American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Or...( NEW YORK March 9 Asia-FirstCall/ ...),Health

NEW YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, announced today that the Company is initiating a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence (UI) in the United States. The Company currently manufactures and markets the oral capsule in China under the Cease Enuresis Oral Capsule brand, which was approved by China's State Food and Drug Administration ("SFDA") in 2002.

UI has a significant impact on its sufferers' quality of life and is associated with embarrassment, stigma, and shame. According to Decision Resources, there were 400-500 million sufferers of urinary incontinence (UI) worldwide in 2007.

The U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug (IND) for AOBO-001 in late 2008. The U.S. clinical trial phase one will commence shortly in order to evaluate the safety of AOBO- 001 in American populations. During the development of AOBO-001 in the U.S., various preclinical and clinical studies also will be conducted in China or other regions in order to expedite the development process, and all studies will be subject to relevant U.S. FDA regulations.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "This is an important milestone in our product development initiatives. We have observed the efficacy of AOBO-001 on urinary incontinence in Chinese populations since 2002 when we launched Cease Enuresis Oral Capsules in China. When the first herbal drug, Veregen
'/>"/>